South Korean government study also shows that NPEs continue to target foreign defendants in places like Marshall, Texas (pictured) post TC Heartland
Vivo is firmly in the same smartphone sales tier as companies like Oppo and Xiaomi, but it has pursued a low-key IP strategy very different to that of its chief rivals
The auto company is the biggest shareholder in the parts giant, a growing IP power which is ramping up its ability to make electric vehicle parts
Lack of IP funds and staff at Kyoto University may have left immunotherapy pioneer Tasuku Honjo with a poor deal in agreement with Ono Pharmaceutical.
A surprise inspection at the Swedish giant’s Beijing office sets the stage for the first big IP probe by China’s new super-regulator
In an interview with IAM, firm president Joe Siino (pictured, far right) also confirms expansion of operations in Hong Kong, with former Technicolor licensing head Deirdre Leane soon to join the team
The high invalidation rate for life science patents in China has created a headache for drug companies and a money-making opportunity for enterprising individuals
Firms welcomed tougher measures against infringers at IPBC Korea 2019 last week, but there are concerns about a recent initiative to attract more foreign litigants through the use of English-language hearings
The Japanese automaker is ‘opening up’ patents related to hybrid electric vehicle technology that it has previously licensed to Nissan, Ford, Subaru and Mazda, in a move that expands on its previous fuel cell pledge
An inside look at Huawei’s patent buying strategy, TCL’s safeguards against over-investment, Baidu’s IP shift and much more from IPBC Shenzhen
Regulations in the special economic zone once known primarily as a den of piracy will allow fast-track administrative injunctions and impose stiff penalties on repeat infringers
"The business places more and more scrutiny on patent spend, and asks the patent team to quantify the value proposition and return on investment,” says David Dutcher
CNIPA has promised to reduce examination times, but users are more concerned about quality. Agency's deputy director waves off the suggestion that 90% of its issued patents are 'junk'
A*STAR’s head of IP and corporate services Suresh Sachi sets out his approach to partnering with biopharma innovators, the exclusivity-related stumbling blocks – and how to overcome them
After nine years of legal manoeuvring, the US chipmaker has won approval for its licensing practices in Japan. But in other parts of the region, antitrust doubts remain